MedTrace Logo

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

NCT04592666 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2020-10-19

No results posted yet for this study

Summary

Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study

Conditions

  • Lung Cancer, Non-small Cell
  • EGFR T790M
  • EGFR Gene Mutation

Interventions

DRUG

Almonertinib

the standard therapy of single agent almonertinib

DRUG

Pemetrexed

standard dose

DRUG

Carboplatin

AUC=5

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-09
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04592666 on ClinicalTrials.gov